This is Evusheld, the AstraZeneca drug against covid: how it works and who can take it

In a constant race to continue reducing daily infections, in the last week to the use of a new drug against covid-19. Hand in hand with AstraZeneca, one of the pioneering companies in the development of the vaccine, the administration of Evusheld can already be provided in certain groups of patients.

Despite the fact that it is proven that the administration of vaccines is the best remedy against coronavirus, there are certain people who, due to their physical conditions, cannot be inoculated with some of the doses approved by the World Health Organization (WHO). Also due to the fact that the vaccine can have harmful effects on certain organisms, for this, the development of less harsh medicines is sought.

One of them, in recent weeks, has been another big pharmacist who has finished giving the go-ahead to its remedy against the disease. AstraZeneca, fully involved in the fight against SARS-CoV-2 since the start of the pandemic.

A drug that already has the approval of all health institutions with decision-making capacity in Europe and that Spain has recently acquired in a batch of up to 30,000 doses. This was confirmed by the Minister of Health, Carolina Darias herself, emphasizing that this signing with the British company strengthens the fight against covid-19.

How does Evusheld work?

Being the first drug “that pursues an indication of pre-exposure prophylaxis, which is the unmet medical need that arises, precisely, among immunocompromised patients”, as reported by La Moncloa, it is a combination of two monoclonal antibodies that It serves as protection in people who cannot receive the vaccines or in those who do not produce the desired effect.

See also  Permanent disability pensions: these are the minimum amounts for 2021

Who can take Evusheld?

Developed, therefore, for immunocompromised patients, this drug is intended for people over 18 years of age with immunodeficiencies, solid organ transplant recipients, or people treated for hematological malignancies with drugs that inhibit their ability to generate immunity against the antigen injected with the vaccines.

Its implementation takes place in two doses and its effects last up to six months in which the body generates a complete defense against the coronavirus, as if it were a vaccine.

Loading Facebook Comments ...
Loading Disqus Comments ...